DOBOT grants 2.50 million H-share options; chairman’s allotment requires shareholder vote

Bulletin Express
04/02

Shenzhen DOBOT Corp Ltd (DOBOT) has approved the issuance of 2.50 million H-share options to six employee participants under its H Share Option Scheme, according to a filing with the Hong Kong Stock Exchange on 2 April 2026.

The grant covers four directors and two other employees. Directors receive 2.30 million options—92% of the total—including 1.00 million options for Chairman and General Manager Liu Peichao, 0.50 million each for Executive Directors Wang Yong and Jiang Yu, and 0.30 million for Non-executive Director Lang Xulin. The combined director allocation equals 0.58% of DOBOT’s issued H shares.

Key terms • Exercise price: HK$33.34 per H share, matching the 2 April 2026 closing price and exceeding the five-day average of HK$33.20. • Vesting schedule: Four equal tranches of 25% on 3 April in 2027, 2028, 2029 and 2030. • Exercise window: Three years from each vesting date. • Performance hurdles: Vesting is linked to both group revenue growth against FY 2025 and individual performance ratings. Full vesting requires revenue growth of ≥40% in 2026, ≥96% in 2027, ≥174.40% in 2028 and ≥284.16% in 2029, along with an “A” individual rating. • Clawback: Options may be cancelled or shares reclaimed in cases such as financial misstatement, fraud or serious misconduct. • Financial assistance: None provided for option exercise.

Regulatory considerations Because Mr Liu’s allotment exceeds the 0.1% individual limit within a 12-month period, shareholder approval is required at a forthcoming general meeting; Mr Liu, his associates and core connected persons must abstain from voting.

Scheme capacity Following this grant, DOBOT states that up to 31.35 million H shares remain available for future issuance under its various equity incentive schemes.

Purpose The board cites talent retention, performance alignment and value creation as the objectives of the option grant.

The independent non-executive directors have reviewed and approved all director allocations in accordance with Hong Kong Listing Rule 17.04(1).

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10